Table 1.
Characteristics of patients and tumour samples.
| Patient | Primary NMIBC | NMIBC Recurrence | MIBC | Common SNV in Seq. Samples | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No | Age | Sex | TNM-T/Grading | RFS [m] | TNM-T/Grading | RFS [m] | TNM-T/Grading | PFS [m] | TNM-T/Grading | |
| 1 | 67 | m | pTa HG | 59 | pT1 HG | 15 | pT4a HG | 13.9% | ||
| 2 | 79 | w | pT1 HG | 15 | pTa LG | 23 | 3x pTa HG | 5 | pT2b HG | 65.8% |
| 3 | 69 | m | pTa HG | 10 | pT4a HG | 22.8% | ||||
| 4 | 78 | w | pT1 HG | 30 | pTa HG | 12 | pT4a HG | 28.1% | ||
| 5 | 65 | m | pTa HG | 13 | PUNLMP | 21 | pT2a HG | 2.2% | ||
| 6 | 71 | m | pT1 HG | 10 | pTa LG | 41 | pT1 LG | 23 | pT2a HG | 12.6% |
| 7 | 74 | m | pTa HG | 42 | pT3a HG | 0.9% | ||||
| 8 | 73 | m | pTa LG | 62 | pT2 HG | 0.6% | ||||
| 9 | 63 | m | pTa HG | 29 | pTa HG | 10 | pT2a HG | |||
| 10 | 76 | m | pTa HG | 16 | pT3b HG | |||||
| 11 | 76 | m | pTa HG | 14 | pTa HG | 5 | pTa LG | 28 | pT4a HG | |
Bold: exome-wide sequenced tumors; NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer; RFS, recurrence free survival; PFS, progression free survival; TNM-T, classification of size and extension of malignant tumors, LG, low grade; HG, high grade; PUNLMP, papillary urothelial neoplasm of low malignant potential; com. SNV, common single nucleotide variations.